Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Next Generation Flow Cytometry for Global Immunological Profile, Response And Toxicity Biomarker Signatures in Cutaneous Squamous Cell Carcinoma Under CEmiplimab Treatment.

NCT07064330 is registered in ClinicalTrials.gov with Instituto de Investigación Biomédica de Salamanca as lead sponsor.

NCT NCT07064330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07064330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Next Generation Flow Cytometry for Global Immunological Profile, Response And Toxicity Biomarker Signatures in Cutaneous Squamous Cell Carcinoma Under CEmiplimab Treatment.
Lead sponsor
Instituto de Investigación Biomédica de Salamanca
Phase
Observational
Overall status
Recruiting
Start date
July 17, 2025
Completion date
June 30, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous squamous cell carcinoma (cscc)